Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology

Posted on by stom_admin

Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”) are pleased to announce a strategic drug discovery collaboration on an undisclosed target. Under the terms of the agreement, Vernalis and Contera will use their respective expertise in fragment and structure-based drug design […]

Contera Pharma signs agreement with BDD Pharma for development of a novel tablet formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease

Posted on by stom_admin

Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, has entered into collaboration with BDD Pharma, a drug delivery company specializing in modified and controlled release oral formulations, to begin the development of a novel formulation of levodopa / carbidopa (CP-012) to specifically treat Parkinson´s disease (PD) patients suffering from nocturnal or […]

Abzu and Contera Pharma partner to design RNA therapeutics for rare diseases using xAI technology

Posted on by stom_admin

Abzu, an applied research startup who has developed a pioneering explainable artificial intelligence (xAI), and Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, are partnering to design nucleic acid-based medicines. Abzu will collaborate exclusively with Contera Pharma on two undisclosed targets within rare neurological diseases. According to recent research in European […]

Contera Pharma elected new executive management team

Posted on by stom_admin

Contera Pharma, a subsidiary of Bukwang, announced that it elected Dr. Thomas Sager as CEO while further expanding the executive management team to include representatives for Business Development and R&D Chief Executive Officer; Thomas Sager, PhD. Chief Business Officer; Anders Brandt Elvang, PhD. Chief Science Officer; Kenneth Vielsted Christensen, PhD. Thomas Sager, received his PhD […]

Contera Pharma, subsidiary of Bukwang, raises 51 billion KRW in Series B financing round

Posted on by stom_admin

Contera Pharma (“Contera”), subsidiary of Bukwang Pharmaceutical (“Bukwang”), announced 51 billion KRW Series B financing from Korean institutional investors. The size of the current round has increased more than 17-fold compared to series A financing in 2019. Contera, is focused on developing innovative drugs for the treatment of debilitating central nervous system (CNS) disorders. The […]

Contera Pharma opens office in Seoul, Korea

Posted on by stom_admin

To strengthen its activities Contera Pharma has today opened an office in Seoul, Korea. The Seoul office will be headed by Minchang Kwon, Managing Director and Jai Hong Kwon, CFO. John Bondo Hansen, CEO says: Our new Seoul office will be a valuable addition to the Contera organization. I warmly welcome Minchang Kwon and Jai […]